Windtree Therapeutics, a struggling biotech firm that rebranded itself around holding BNB reserves, is set to be delisted from the Nasdaq after its stock collapsed below the exchange’s minimum price requirement. According to a filing with the Securities and Exchange Commission, Nasdaq will remove Windtree from its listings on Aug. 21 after the company failed
The post BNB treasury company faces delisting from Nasdaq on Aug. 21 appeared first on CryptoSlate. CryptoSlate Read More
About The Author
